| Description | GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential. |
| In vitro | GSK-A1 is a selective?type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα)?inhibitor with a?pIC50?of 8.5-9.8[3]. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2[3]. |
| Target activity | PI4KA:8.5-9.8 (pIC50), PI4K2A:<5 (pIC50), PI4K2B:<5 (pIC50), PI4KB:7.2-7.7 (pIC50) |
| molecular weight | 574.63 |
| Molecular formula | C29H27FN6O4S |
| CAS | 1416334-69-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Beebe SJ, Reimann EM, Schlender KK. Purification and characterization of a cAMP- and Ca2+-calmodulin-independent glycogen synthase kinase from porcine renal cortex. J Biol Chem. 1984 Feb 10;259(3):1415-22. PubMed PMID: 6319398. |